Chemokine programming dendritic cell antigen response: Part I - select chemokine programming of antigen uptake even after maturation

Immunology

Volumn 139, Issue 1, 2013, Pages 72-87

  Park, Jaehyung ^a   Wu, Cindy T ^a   Bryers, James D ^a  

^a University of Washington   (United States)

Author keywords

Antigen uptake processing; Chemokines; Dendritic cell; Vaccine efficiency

Indexed keywords

CELL ANTIGEN; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; BIOENGINEERING; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL MATURATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; EX VIVO GENE TRANSFER; INNATE IMMUNITY; INTERNALIZATION; LEUKOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGEN PRESENTATION; CELL LINE; CHEMOKINE CCL19; CHEMOKINE CCL3; DENDRITIC CELLS; MICE; VACCINES;

EID: 84876063882     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12056     Document Type: Article

References (68)

1. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045.
2. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
3. Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2010; 2:57-68.
4. Sexton A, Whitney PG, Chong SF et al. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 2009; 3:3391-400.
5. Feng HP, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003; 101:245-52.
6. Zabaleta A, Llopiz D, Arribillaga L et al. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol Ther 2008; 16:210-7.
7. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34.
8. Steele JC, Rao A, Marsden JR et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther 2011; 18:584-93.
9. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 2011; 10:3
10. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115:33-42.
11. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006; 58:32-45.
12. Heit A, Busch DH, Wagner H, Schmitz F. Vaccine protocols for enhanced immunogenicity of exogenous antigens. Int J Med Microbiol 2008; 298:27-32.
13. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 2009; 462:449-60.
14. Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009; 8:151-8.
15. Ali OA, Mooney DJ. Sustained GM-CSF and PEI condensed pDNA presentation increases the level and duration of gene expression in dendritic cells. J Control Release 2008; 132:273-8.
16. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997; 77:759-803.
17. Platt CD, Ma JK, Chalouni C, Ebersold M, Bou-Reslan H, Carano RAD, Mellman I, Delamarre L. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci U S A 2010; 107:4287-92.
18. Zhou XF, Liu B, Yu XH et al. Controlled release of PEI/DNA complexes from mannose-bearing chitosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine. J Control Release 2007; 121:200-7.
19. Birkholz K, Schwenkert M, Kellner C et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010; 116:2277-85.
20. Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 2011; 32:3094-105.
21. Tacken PJ, De Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802.
22. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-8.
23. McColl SR. Chemokines and dendritic cells: a crucial alliance. Immunol Cell Biol 2002; 80:489-96.
24. Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188:373-86.
25. Foti M, Granucci F, Aggujaro D et al. Upon dendritic cell (DC) activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of DC at the inflammatory site. Int Immunol 1999; 11:979-86.
26. Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999; 162:3859-64.
27. Stachowiak AN, Wang Y, Huang YC, Irvine DJ. Homeostatic lymphoid chemokines synergize with adhesion ligands to trigger T and B lymphocyte chemokinesis. J Immunol 2006; 177:2340-8.
28. Dimberg A. Chemokines in angiogenesis. Curr Top Microbiol 2010; 341:59-80.
29. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008; 15:49-58.
30. Bachmann MF, Kopf M, Marsland BJ. Chemokines: more than just road signs. Nat Rev Immunol 2006; 6:159-64.
31. Marsland BJ, Battig P, Bauer M et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 2005; 22:493-505.
32. Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in search of the 'epimmunome'. Nat Immunol 2010; 11:656-65.
33. H2 and tolerogenic responses. Nat Immunol 2010; 11:647-55.
34. Piemonti L, Monti P, Allavena P, Leone BE, Caputo A, Di Carlo V. Glucocorticoids increase the endocytic activity of human dendritic cells. Int Immunol 1999; 11:1519-26.
35. Clingan JA, Yanagawa Y, Iwabuchi K, Onoe K. Effect of T helper 1 (Th1)/Th2 cytokine on chemokine-induced dendritic cell functions. Cell Immunol 2006; 242:72-9.
36. Yanagawa Y, Onoe K. CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 2003; 101:4923-9.
37. Yanagawa Y, Onoe K. CCR7 ligands induce endocytosis and the formation of actin-filled ruffles in mature dendritic cells. J Clin Exp Hematop 2005; 45:25-35.
38. Koller MR, Bender JG, Papoutsakis ET, Miller WM. Effects of synergistic cytokine combinations, low oxygen, and irradiated stroma on the expansion of human cord blood progenitors. Blood 1992; 80:403-11.
39. Souza KLA, Elsner M, Mathias PCF, Lenzen S, Tiedge M. Cytokines activate genes of the endocytotic pathway in insulin-producing RINm5F cells. Diabetologia 2004; 47:1292-302.
40. Hot A, Lenief V, Miossec P. Combination of IL-17 and TNF α induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis 2012; 71:768-76.
41. Lutz MB, Kukutsch N, Ogilvie ALJ, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77-92.
42. Lutz MB, Suri RM, Niimi M, Ogilvie AL, Kukutsch NA, Rossner S, Schuler G, Austyn JM. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30:1813-22.
43. Yu P, Xiong S, He Q, Chu Y, Lu C, Ramlogan CA, Steel JC. Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts. Immunology 2009; 127:500-11.
44. Kotzor N, Lechmann M, Zinser E, Steinkasserer A. The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology 2004; 209:129-40.
45. Imai J, Hasegawa H, Maruya M, Koyasu S, Yahara I. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. Int Immunol 2005; 17:45-53.
46. Oura J, Tamura Y, Kamiguchi K, Kutomi G, Sahara H, Torigoe T, Himi T, Sato N. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells. Int Immunol 2011; 23:223-37.
47. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class-II compartment - down-regulation by cytokines and bacterial products. J Exp Med 1995; 182:389-400.
48. Hauser J, Ellisman M, Steinau HU, Stefan E, Dudda M, Hauser M. Ultrasound enhanced endocytotic activity of human fibroblasts. Ultrasound Med Biol 2009; 35:2084-92.
49. Kikuchi K, Yanagawa Y, Onoe K. CCR7 ligand-enhanced phagocytosis of various antigens in mature dendritic cells - time course and antigen distribution different from phagocytosis in immature dendritic cells. Microbiol Immunol 2005; 49:535-44.
50. Zallone AZ, Teti A, Primavera MV, Naldini L, Marchisio PC. Osteoclasts and monocytes have similar cytoskeletal structures and adhesion property in vitro. J Anat 1983; 137:57-70.
51. West MA, Prescott AR, Chan KM, Zhou ZJ, Rose-John S, Scheller J, Watts C. TLR ligand-induced podosome disassembly in dendritic cells is ADAM17 dependent. J Cell Biol 2008; 182:993-1005.
52. Gawden-Bone C, Zhou ZJ, King E, Prescott A, Watts C, Lucocq J. Dendritic cell podosomes are protrusive and invade the extracellular matrix using metalloproteinase MMP-14. J Cell Sci 2010; 123:1427-37.
53. West MA, Wallin RPA, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, Prescott AR, Watts C. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 2004; 305:1153-7.
54. + T-cell-dendritic cell interactions induce migration of immature dendritic cells through dissolution of their podosomes. Blood 2008; 111:3579-90.
55. Mackay DJG, Hall A. Rho GTPases. J Biol Chem 1998; 273:20685-8.
56. Garrett WS, Chen LM, Kroschewski R, Ebersold M, Turley S, Trombetta S, Galan JE, Mellman I. Developmental control of endocytosis in dendritic cells by Cdc42. Cell 2000; 102:325-34.
57. Yanagawa Y, Onoe K. CCL19 induces rapid dendritic extension of murine dendritic cells. Blood 2002; 100:1948-56.
58. Sallusto F, Lanzavecchia A. Efficient presentation of soluble-antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor-necrosis-factor-α. J Exp Med 1994; 179:1109-18.
59. Menges M, Rossner S, Voigtlander C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002; 195:15-21.
60. Xia CQ, Peng RH, Annamalai M, Clare-Salzler MJ. Dendritic cells post-maturation are reprogrammed with heightened IFN-γ and IL-10. Biochem Biophys Res Commun 2007; 352:960-5.
61. Geisel J, Kahl F, Muller M, Wagner H, Kirschning CJ, Autenrieth IB, Frick JS. IL-6 and maturation govern TLR2 and TLR4 induced TLR agonist tolerance and cross-tolerance in dendritic cells. J Immunol 2007; 179:5811-8.
62. Rulle S, Kioon MDA, Asensio C, Mussard J, Ea HK, Boissier MC, Liote F, Falgarone G. Adrenomedullin, a neuropeptide with immunoregulatory properties induces semi-mature tolerogenic dendritic cells. Immunology 2012; 136:252-64.
63. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31:331-41.
64. Jiang X, Shen C, Rey-Ladino J, Yu H, Brunham RC. Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity. Infect Immun 2008; 76:2392-401.
65. + T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE 2010; 5:e11144.
66. Cho NH, Cheong TC, Min JH et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol 2011; 6:675-82.
67. Martin-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198:615-21.
68. Wilson NS, El-Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath WR, Shortman K, Villadangos JA. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 2003; 102:2187-94.